| Name | [Pyr1]-Apelin-13 |
| Description | [Pyr1]-Apelin-13 ([pGlu1]-Apelin-13) is a potent and selective endogenous Apelin receptor (APJ) agonist. |
| In vitro | Encapsulation of [Pyr1]-apelin-13 in lipoPEG particles (lipoPEG-PA13) enables sustained and extended drug release in both in vitro and in vivo conditions[1]. |
| In vivo | In a study involving a mouse model of pressure-overload induced heart failure, nanocarriers containing [Pyr1]-apelin-13 demonstrated a prolonged effect in preventing cardiac dysfunction, highlighting its potential therapeutic benefits. Additionally, [Pyr1] apelin-13 at doses of 1 and 5 μg was found to enhance locomotor activity, alleviate pain symptoms, decrease cavity size, and reduce caspase-3 levels in rats, indicating its analgesic and anti-inflammatory properties. Furthermore, the compound significantly increased thermal paw withdrawal latency and, at a 5 μg dose, notably improved paw withdrawal threshold in comparison to spinal cord injury (SCI) animals from the second week post-SCI, suggesting its effectiveness in pain management and functional recovery post-SCI. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 125 mg/mL (81.5 mM), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | endogenous apelin | Apelinreceptor | Apelin receptor | [Pyr1]-Apelin-13 | [Pyr-1]-Apelin-13 | [Pyr1]Apelin13 | [Pyr1] Apelin 13 |
| Inhibitors Related | Apelin agonist 1 | 1-Methyl-3-phenylpropylamine | ML339 | ELA-14(human) acetate | BMS-986224 | ELA-11 (human) acetate(1784687-32-6 free base) | Apelin-12 acetate | APJ receptor agonist 8 | AM-8123 | Azelaprag | (2R,3S)-Azelaprag | CMF019 |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Peptide Compound Library | NO PAINS Compound Library | Bioactive Compounds Library Max | GPCR Compound Library |